Abstract LB331: First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Jeeyun Lee(Samsung Medical Center), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Roy Rabbie(AstraZeneca (Poland)), Arthur W. Lambert(AstraZeneca (South Korea)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Mariusz Kwiatkowski, Caron Lloyd(AstraZeneca (Netherlands)), Aitana Calvo Ferrándiz(Hospital General Universitario Gregorio Marañón), Hanneke van Laarhoven(Amsterdam University Medical Centers), Sara Lonardi(Istituto Oncologico Veneto), Keun-Wook Lee(Seoul National University Bundang Hospital), Xinjun Liang(Hubei Cancer Hospital), Megan Scott(AstraZeneca (Singapore)), Tianshu Liu(Shanghai Medical College of Fudan University), Kohei Shitara(National Cancer Center Hospital East), Sun Young Rha(Yonsei University), Hirokazu Shoji(National Cancer Center), Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 0
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k